glp-1 receptor agonists in idiopathic intracranial hypertension After Abrupt Cessation of Medication: A Case Report of Abrupt Glucagon-Like Peptide-1 (GLP-1) Agonist Cessation and Review of the Literature GLP-1 medications and pseudotumor cerebri

2012;59(10):A4519

If your primary concern is blood sugar management and diabetes care, Ozempic may be the preferred choice

Known for innovation and a robust pipeline, contributing through advanced treatments and expanding the market reach

Balanced Perspective: Conditional Game Changer The evidence suggests that GLP-1 agonists represent a conditional game changertransformative for appropriate patients with adequate access and support, but with significant limitations that prevent universal application

Atrium can help patients prepare by documenting BMI, weight-related conditions, prior treatment history, medication tolerance, labs, and the clinical reason a GLP-1 is being considered

1.1 per 1,000 person-years